Testing effectiveness (Phase 2)Ended earlyNCT01773785
What this trial is testing
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Who this might be right for
Biliary Cancer
Spectrum Pharmaceuticals, Inc 30